This site is intended for healthcare professionals

The next global epidemic

Read time: 5 mins
Last updated:21st Aug 2020
Published:2nd Sep 2020
Despite damaging the liver, most people with NASH are not aware that they have a liver problem. In this series of articles, we share the epidemiology and current management strategies of NASH as well as the potential for new drug therapies.

As the levels of obesity around the globe continually grow, Non-alcoholic Steatohepatitis, or NASH, is rapidly becoming a serious health concern. NASH is estimated to affect 3 – 5% of the global population; well over two hundred million people worldwide1

Yet, despite its prevalence and severity, there are still no drug therapies approved for the treatment of NASH.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.